The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multisite validation of a 92-gene molecular classifier: Diagnostic accuracy and clinical utility in metastatic cancer.
Catherine A. Schnabel
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Sarah E Kerr
Research Funding - bioTheranostics
Peggy S Sullivan
Research Funding - bioTheranostics
Yi Zhang
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Veena Singh
Employment or Leadership Position - bioTheranostics
Stock Ownership - Veena Singh
Brittany Carey
Research Funding - bioTheranostics
Mark G. Erlander
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
W Edward Highsmith
Research Funding - bioTheranostics
Sarah M Dry
Research Funding - bioTheranostics
Elena F Brachtel
Research Funding - bioTheranostics